GLPGF Galapagos NV (PK)

Galapagos  NV (Euronext: GLPG) announced
today  that its Board of Directors has created and offered 75,000 warrants under
a new warrant plan.

On  18 September 2013, the Board of Directors of Galapagos approved the "Warrant
Plan  2013 (B)" within  the  framework  of  the  authorized capital.  Under this
warrant  plan, 75,000 warrants were created  (subject to acceptance) and offered
to  David Smith, who joined Galapagos' Executive Committee as CEO of the service
division.

These  warrants have an exercise term of eight years as of the date of the offer
and  have an exercise price of €15.18 (the average closing price of the share on
Euronext  Brussels during  the thirty  days preceding  date of  the offer).  The
warrants are not transferable and can in principle not be exercised prior to the
end  of  the  third  calendar  year  after  the calendar year in which they were
granted.   Each warrant gives the right to subscribe to one new Galapagos share.
 Should  the warrants be exercised, Galapagos will  apply for the listing of the
resulting new shares on a regulated stock market.  The warrants as such will not
be listed on any stock market.

To  date, Galapagos' total  share capital amounts  to €160,962,030.82; the total
number  of securities conferring voting rights  is 29,755,302, which is also the
total number of voting rights (the "denominator"), and all securities conferring
voting  rights and all voting rights are of the same category.  The total number
of rights (warrants) to subscribe to not yet issued securities conferring voting
rights  is 3,636,015, which  equals the  total number  of voting rights that may
result from the exercise of these warrants.

About Galapagos
Galapagos  (Euronext: GLPG; OTC: GLPYY) is specialized in novel modes-of-action,
with  a large pipeline of  five Phase 2 (two led  by GSK), one Phase 1, six pre-
clinical,  and  20 discovery  small-molecule  and  antibody  programs  in cystic
fibrosis, inflammation, antibiotics, metabolic disease, and other indications.
GLPG0634  is an orally-available, selective inhibitor  of JAK1 for the treatment
of  rheumatoid arthritis and potentially  other inflammatory diseases, currently
in  Phase  2B studies  in  RA  and  about  to  enter  Phase 2 studies in Crohn's
disease.   AbbVie  and  Galapagos  signed  a worldwide license agreement whereby
AbbVie  will be responsible for  further development and commercialization after
Phase  2B.  Galapagos has another  selective JAK1 inhibitor  in Phase 2 in lupus
and  psoriasis, GSK2586184 (formerly GLPG0778, in-licensed by GlaxoSmithKline in
2012).  GLPG0974  is the first inhibitor of  FFA2 to be evaluated clinically for
the  treatment of IBD; this program is  currently in a Proof-of-Concept Phase 2
study.    GLPG1205  is  a  first-in-class  molecule  that  targets  inflammatory
disorders and is currently in a First-in-Human Phase 1 study.
The  Galapagos Group, including fee-for-service  companies BioFocus, Argenta and
Fidelta,  has around  800 employees and  operates facilities  in five countries,
with   global  headquarters  in  Mechelen,  Belgium.   Further  information  at:
www.glpg.com

Contact
Galapagos NV
Elizabeth Goodwin, Director Investor Relations
Tel: +31 6 2291 6240
ir@glpg.com

Galapagos forward-looking statements
This release may contain forward-looking statements, including, without
limitation, statements containing the words "believes," "anticipates,"
"expects," "intends," "plans," "seeks," "estimates," "may," "will," "could,"
"stands to," and "continues," as well as similar expressions. Such forward-
looking statements may involve known and unknown risks, uncertainties and other
factors which might cause the actual results, financial condition, performance
or achievements of Galapagos, or industry results, to be materially different
from any historic or future results, financial conditions, performance or
achievements expressed or implied by such forward-looking statements. Given
these uncertainties, the reader is advised not to place any undue reliance on
such forward-looking statements. These forward-looking statements speak only as
of the date of publication of this document. Galapagos expressly disclaims any
obligation to update any such forward-looking statements in this document to
reflect any change in its expectations with regard thereto or any change in
events, conditions or circumstances on which any such statement is based, unless
required by law or regulation.

Galapagos creates new warrant plan: http://hugin.info/133350/R/1729957/578054.pdf

[HUG#1729957]

Grafico Azioni Galapagos NV (PK) (USOTC:GLPGF)
Storico
Da Mag 2024 a Giu 2024

Grafico Azioni Galapagos NV (PK) (USOTC:GLPGF)
Storico
Da Giu 2023 a Giu 2024